Compulsory Vaccination Against Terrorist Attack Is Unjustified, Author Says

Article

The compulsory use of vaccines to prevent the effects of a bioterrorist attack seems to be based on an unproved threat, according to an editorial in this week's British Medical Journal.

 

In 1997 the United States began a compulsory anthrax vaccination program for military personnel. In 2002, a similar program also involving civilians, was started against smallpox. Yet these programs rely on old vaccines for which relatively few data exist, writes Tom Jefferson.

 

For instance, no large scale trial of the US anthrax vaccine (AVA) has ever been conducted, and trials of the current smallpox vaccine have recently been halted because of safety concerns. Despite this, the website of the United States anthrax vaccine immunization program claims proved protection against inhalation anthrax, says the author. Newer vaccines are currently being developed but are a long way from field testing.

 

"Although field trials are expensive and complex, investment in evaluation and in better and safer vaccines surely must be a requisite to have credible compulsory immunization programs involving huge numbers of adults of reproductive age," adds the author. "Until such time, the choice of whether to be vaccinated or not should be left to the individual."

 

To view the full editorial, go to:

http://press.psprings.co.uk/bmj/september/edit524.pdf

 

Reference: BMJ 4 September 2004 edition. Editorial: Bioterrorism and compulsory vaccination BMJ Volume 329, pp 524-5.

 

Source: British Medical Journal

 

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.